Commentary
Podcast
Although it has some daunting adverse effects, Glenn Short, PhD, said ibogaine offers unique biological and therapeutic effects.
This month, we spoke with Glenn Short, PhD, senior vice president of Early Development at atai Life Sciences, about an under-discussed psychedelic drug: ibogaine. Although it has some daunting adverse effects, Short said ibogaine offers unique biological and therapeutic effects.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.